Unum Therapeutics Inc. — Form D
Unum Therapeutics Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-07-21. The offering totals $44.8M, of which $44.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-07-21
- Form: D
- Accession: 0001622229-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $44.8M
- Amount sold: $44.8M
- Investors: 2
- Date of first sale: 2020-07-06
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-371480
Issuer
- Name: Unum Therapeutics Inc.
- CIK: 0001622229
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2014
- Address: 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140
- Phone: 617-945-5576
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Bruce Booth | Director | Cambridge, MA |
| Ben Auspitz | Director | Cambridge, MA |
| Liam Ratcliffe | Director | New York, NY |
| Charles Wilson | Director | Chicago, IL |
| Charles Wilson | Executive Officer | Chicago, IL |
| Matthew L Ros | Director | Cambridge, MA |
| John L Green | Executive Officer | Cambridge, MA |
| Arlene L Morris | Director | Cambridge, MA |
| Jessica L Sachs | Executive Officer | Cambridge, MA |
| Chris L Cain | Director | Cambridge, MA |
| Karen L Ferrante | Director | Cambridge, MA |
| Peter L Harwin | Director | Cambridge, MA |
| Christiana Stamoulis | Executive Officer | Cambridge, MA |
Other filings by this issuer (3)
More